Dengue is endemic in tropical regions and bleeding, ranging from minor to life-threatening, is a dreaded complication. With the increasing incidence of atherosclerotic cardiovascular disease in low- to middle-income countries where Dengue is prevalent, whether to stop or continue antiplatelet agents in patients with thrombocytopenia is a clinical conundrum.
DhanoaARajasekaramGHassanSS, et al.Risk factors and clinical outcome of profound thrombocytopenia in adult patients with DENV infections. Platelets2017; 28: 724–727.
2.
DasSAbreuCHarrisM, et al.Severe thrombocytopenia associated with dengue fever: an evidence-based approach to management of thrombocytopenia. Case Rep Hematol2022; 2022: 1–3.
